304 related articles for article (PubMed ID: 11275701)
1. Established clinical use of octreotide and lanreotide in oncology.
Oberg K
Chemotherapy; 2001; 47 Suppl 2():40-53. PubMed ID: 11275701
[TBL] [Abstract][Full Text] [Related]
2. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
3. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
Igaz P
Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
[TBL] [Abstract][Full Text] [Related]
5. Commentary: Somatostatin analogs-How we choose, and why.
Reidy-Lagunes D; Raj N; Saltz L
Semin Oncol; 2017 Apr; 44(2):157-158. PubMed ID: 28923214
[No Abstract] [Full Text] [Related]
6. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
7. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B
Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956
[TBL] [Abstract][Full Text] [Related]
8. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
9. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.
Dogliotti L; Tampellini M; Stivanello M; Gorzegno G; Fabiani L
Ann Oncol; 2001; 12 Suppl 2():S105-9. PubMed ID: 11762334
[TBL] [Abstract][Full Text] [Related]
10. The place of somatostatin analogs in the diagnosis and treatment of the neuoroendocrine glands tumors.
Melen-Mucha G; Lawnicka H; Kierszniewska-Stepien D; Komorowski J; Stepien H
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):237-54. PubMed ID: 18221040
[TBL] [Abstract][Full Text] [Related]
11. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
14. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
Gardner-Roehnelt NM
Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Kvols L
World J Gastroenterol; 2010 Jun; 16(24):2963-70. PubMed ID: 20572298
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic strategies for neuroendocrine tumours--can eminence replace evidence?
Zedenius J
Acta Oncol; 2008; 47(1):3-4. PubMed ID: 17891671
[No Abstract] [Full Text] [Related]
17. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
Arnold R; Simon B; Wied M
Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
[TBL] [Abstract][Full Text] [Related]
18. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin agonists for treatment of acromegaly.
Ben-Shlomo A; Melmed S
Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
Janson ET; Oberg K
Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
[No Abstract] [Full Text] [Related]
[Next] [New Search]
